Gingival Recession Types One(RT1)NCT07877064
Comparison of Connective Tissue and PRF in Gingival Recession
A study testing Titanium-prepared Platelet-Rich Fibrin and SCTG + CAF in people with Gingival Recession Types One(RT1) and Gingival Crevicular Fluid, run by Ataturk University.
Trial summary
Aim: In this study, it was aimed to comparatively investigate the clinical and biochemical effects of subepithelial connective tissue graft and coronally advanced flap (SCTG + CAF) or titanium-prepared platelet rich fibrin and coronally advanced flap (TPRF + CAF ) in the treatment of Miller class I and II gingival… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Gingival Recession Types One(RT1), Gingival Crevicular Fluid
- What is being tested?
- Titanium-prepared Platelet-Rich Fibrin and SCTG + CAF
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2016to 30 Aug 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Absence of any systemic disease that would constitute a contraindication for periodontal treatment or impair wound healing.
- Miller Class I, II gingival recessions
- the tooth is vital and no restoration or decay in cervical region
Who cannot join
- malposition, mobility or travma in the tooth
- smoking
- having any systemic disease
- pregnancy
About this study
Official title: Comparison of Cytokin Levels in Gingival Crevicular Fluid After Use of Titanium-Prepared Platelet Rich Fibrin and Connective Tissue Grafts
Aim: In this study, it was aimed to comparatively investigate the clinical and biochemical effects of subepithelial connective tissue graft and coronally advanced flap (SCTG + CAF) or titanium-prepared platelet rich fibrin and coronally advanced flap (TPRF + CAF ) in the treatment of Miller class I and II gingival recessions.
- Being tested
- Titanium-prepared Platelet-Rich Fibrin, SCTG + CAF
- Keywords
- gingival recession, platelet rich fibrin, connective tissue graft, root coverage, cytokine
- Medical subject headings
- Gingival Recession
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Titanium-prepared Platelet-Rich FibrinProcedure or surgery
Blood samples (approximately 10 mL per tube) are drawn from the antecubital vein
SCTG + CAFProcedure or surgery
connective tissue graft and coronally advanced flap
| Study group | Role | What they receive |
|---|---|---|
| Test Group | Other | Preoperative clinical measurements were taken and DOS samples were obtained from patients who had completed Phase I therapy. Titanium-prepared platelet-rich fibrin and coronally advanced flap (T-PRF + CAF) were performed. Receives: Procedure: Titanium-prepared Platelet-Rich Fibrin |
| Control Group | Other | Preoperative clinical measurements were taken and DOS samples were obtained from patients who had completed Phase I therapy. Subepithelial connective tissue graft and coronally advanced flap (SCTG + CAF) were performed.. Receives: Procedure: SCTG + CAF |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Root Coverage
Description: Percentage of root coverage calculated as [(baseline recession depth - postoperative recession depth) / baseline recession depth] × 100. Recession depth is measured from the cemento-enamel junction (CEJ) to the most apical point of the gingival margin using a periodontal probe.
Measured: Baseline and 6 months postoperatively
Gingival Crevicular Fluid (GCF) Biomarker Levels
Description: GCF levels of measured by ELISA, collected from the treated sites with paper strips.
Measured: Baseline, 1, 3 and 6 months postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2026
- Study start1 Dec 2016
- Primary completion1 Jun 2017
- Study completion30 Aug 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gingival Recession Types One(RT1)Studies of the same condition, open and under way.
- More trials run by Ataturk UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ataturk University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tugba Aydin, Ataturk University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07877064
- Sponsor's protocol ID
- 2016/13
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Cytokin Levels in Gingival Crevicular Fluid After Use of Titanium-Prepared Platelet Rich Fibrin and Connective Tissue Grafts
- ClinicalTrials.gov ID
- NCT07877064
- Acronym / sponsor ID
- 2016/13
- Keywords
- gingival recession, platelet rich fibrin, connective tissue graft, root coverage, cytokine
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Ataturk UniversityUniversity, hospital or other
- Study start
- 1 Dec 2016 (actual)
- Primary completion
- 1 Jun 2017 (actual)
- Study completion
- 30 Aug 2017 (actual)
- First posted
- 16 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim: In this study, it was aimed to comparatively investigate the clinical and biochemical effects of subepithelial connective tissue graft and coronally advanced flap (SCTG + CAF) or titanium-prepared platelet rich fibrin and coronally advanced flap (TPRF + CAF ) in the treatment of Miller class I and II gingival recessions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test Group | Other | Procedure: Titanium-prepared Platelet-Rich FibrinPreoperative clinical measurements were taken and DOS samples were obtained from patients who had completed Phase I therapy. Titanium-prepared platelet-rich fibrin and coronally advanced flap (T-PRF + CAF) were performed. |
| Control Group | Other | Procedure: SCTG + CAFPreoperative clinical measurements were taken and DOS samples were obtained from patients who had completed Phase I therapy. Subepithelial connective tissue graft and coronally advanced flap (SCTG + CAF) were performed.. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Absence of any systemic disease that would constitute a contraindication for periodontal treatment or impair wound healing.
- Miller Class I, II gingival recessions
- the tooth is vital and no restoration or decay in cervical region
Key exclusion criteria (4 listed)
- malposition, mobility or travma in the tooth
- smoking
- having any systemic disease
- pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Titanium-prepared Platelet-Rich FibrinBlood samples (approximately 10 mL per tube) are drawn from the antecubital vein | Procedure or surgery | Test Group |
| SCTG + CAFconnective tissue graft and coronally advanced flap | Procedure or surgery | Control Group |
Primary outcome
Percentage of Root Coverage
Time frame: Baseline and 6 months postoperatively
Description: Percentage of root coverage calculated as [(baseline recession depth - postoperative recession depth) / baseline recession depth] × 100. Recession depth is measured from the cemento-enamel junction (CEJ) to the most apical point of the gingival margin using a periodontal probe.
Gingival Crevicular Fluid (GCF) Biomarker Levels
Time frame: Baseline, 1, 3 and 6 months postoperatively
Description: GCF levels of measured by ELISA, collected from the treated sites with paper strips.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Titanium-prepared Platelet-Rich Fibrin and SCTG + CAF in people with Gingival Recession Types One(RT1) and Gingival Crevicular Fluid, run by Ataturk University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Root Coverage (time frame: Baseline and 6 months postoperatively). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.